.svg){kind=icon}
View all IQVIA events
Featured Speaker
Dr Mohammad Dar
EVP, Head of Clinical Development and Chief Medical Officer, Immunocore
Alexander I. Spira, MD, Ph.D., FACP
Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins
Shannon Xiaoqing Zhang, MD, Ph.D., MBA
Chief Medical Officer Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
David Alsadius, MD, Ph.D.
Solid Tumor Head & Senior Medical Director, IQVIA Oncology Center of Excellence
Murray Aitken
Executive Director, IQVIA Institute for Human Data Science
This webinar is a livestream of the Institute’s pre-ESMO symposium in Madrid and is a non-commercial event open to the public at no cost. Attendance at ESMO is not required. This discussion is designed for a broad oncology audience and will provide relevant insights for patients, clinicians, healthcare providers, non-profits, health economists, and professionals across the pharmaceutical and life sciences sectors.
Phase I oncology trials are evolving rapidly, driven by advances in precision medicine, immunotherapy, and cell and gene therapies. At the same time, China is emerging as a major hub for early oncology development, reshaping global research and regulatory strategies.
This multi-stakeholder symposium will examine how Phase I trials can generate stronger evidence, improve decision-making, and deliver greater value across the oncology development continuum. Topics include:- The evolving role of Phase I trials: Beyond safety to dose optimization, biomarker-driven development, and early efficacy signals.
- Global shifts in oncology innovation: The impact of China’s growing role and increasingly global development strategies.
- Execution under increasing complexity: Balancing speed, scientific advancement, operational demands, and patient value.